2 research outputs found
Isotretinoin-induced spondyloarthropathy-related symptoms: A prospective study
Objective. Acne vulgaris is a chronic inflammatory disease involving the pilosebaceous unit of the skin. Isotretinoin is a systemic retinoid that is often used as an effective treatment option for severe and treatment-resistant acne. Isotretinoin may also cause rheumatologic symptoms. The aim of this prospective observational study was to present followup results regarding the rheumatologic symptoms of patients who received systemic therapy for the treatment of acne (isotretinoin and tetracycline). Methods. For inclusion in the study, all consecutive patients with acne who were aged > 18 years were evaluated by the same dermatologist. The first 42 consecutive patients were included in the isotretinoin group, and after matching for age and sex, 32 consecutive patients were included in the tetracycline group. Isotretinoin treatment was planned as an average dose of 30 mg daily and a total dose of 120-150 mg/kg for 4-6 months. The patients were administered a dose of 1 g/day of tetracycline as 2 equal doses for 3 months. Results. Forty-two patients diagnosed with acne vulgaris were treated with isotretinoin 20.6 ± 4.4 (male/female: 17/22), and 32 patients were treated with tetracycline 20.6 ± 2.7 (male/female: 8/24). There was no significant difference between the 2 groups with respect to age and sex. Unilateral Achilles enthesopathy developed in 3 patients, whereas both Achilles enthesopathy and unilateral sacroiliitis developed in 1 patient. Inflammatory back pain developed in 6 patients in the isotretinoin group. Conclusion. To our knowledge, this was the first prospective observational study that assessed the rheumatologic symptoms of isotretinoin treatment. The spondyloarthropathy findings were identified in 23.1% of the patients who used isotretinoin
Impact of smoking on disease severity in patients with plaque type psoriasis
Background and Design: Psoriasis is a chronic enflammatory systemic disease involving skin, scalp, nails and joints and is characterized by
remission and activation periods. Although the etiopathogenesis of psoriasis has not been fully elucidated, many genetic and environmental
factors are believed to have a role in the development of the disease. Obesity, smoking, family history of psoriasis, repetitive physical traumas
and stress are the factors thought to affect the severity and progress of the disease. In this study, we aimed to investigate the effects of
smoking on the clinical severity of psoriasis in patients with chronic plaque psoriasis.
Materials and Methods: Three hundred outpatients with chronic plaque-type psoriasis were enrolled in the study. Data on age, gender, family
history, smoking history, educational status, history of chronic illness, and psoriasis area severity index (PASI) scores were recorded for each
patient. The effects of these factors on PASI were evaluated.
Results: Current smokers, never smokers and former smokers were compared in terms of disease severity. The median PASI values of current
smokers and never smokers were compared. The mean PASI value was statistically significantly higher in smokers (p=0.049). In multiple logistic
regression analysis, it was detected that the risk of moderate and severe disease increased by male sex 2 times, by family history 2.3 times, and
by smoking period above 20 years, 10 times. In smokers of more than 1 pack a day, this risk further increased.
Conclusion: On the basis of these data, it may be concluded that smoking affects the severity of disease significantly. In addition to amount
of daily cigarette consumption, smoking period was shown to have an effect on the severity of disease. Elimination of risk factors such as
smoking, which appears to increase the severity of diseases, may be helpful in the management of psoriasis